S. 164 — 117th Congress
Advancing Education on Biosimilars Act of 2021
Sponsor
Latest action
Apr 23, 2021Became Public Law No: 117-8.
CRS summary
As of Apr 23, 2021Public Law
Advancing Education on Biosimilars Act of 2021
This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)
The FDA may also maintain and operate a website to provide educational materials about biological products.
Congressional Research Service, via api.congress.gov (public domain)
Roll-call votes
1 on recordApr 14, 2021 · On Motion to Suspend the Rules and Pass
Full roll callYea — 412: 214 D · 198 R
Nay — 8: 8 R
| Member | State |
|---|---|
| Mo Brooks | AL |
| Andy Biggs | AZ |
| Brian J. Mast | FL |
| Andrew S. Clyde | GA |
| Jody B. Hice | GA |
| Thomas Massie | KY |
| Clay Higgins | LA |
| Chip Roy | TX |
Not Voting — 9: 6 R · 3 D
| Member | State |
|---|---|
| Mark Takano | CA |
| Ritchie Torres | NY |
| A. Donald McEachin | VA |
| Lauren Boebert | CO |
| Neal P. Dunn | FL |
| Madison Cawthorn | NC |
| Frank D. Lucas | OK |
| Jodey C. Arrington | TX |
| Kevin Brady | TX |
Member pages currently show roll-call votes from the 119th Congress only. The “Member pages” column marks votes from that congress.